Kisspeptin: Reproductive Axis Regulator — Scientific Analysis

Kisspeptin is an endogenous neuropeptide encoded by the KISS1 gene, acting as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Via the KISS1R receptor (GPR54) on GnRH neurons in the arcuate nucleus, it controls pulsatile GnRH — and consequently LH and FSH — release from the pituitary, being essential for puberty, fertility, and reproductive function in both sexes.

Studies demonstrate that KNDy neurons (co-expressing Kisspeptin, Neurokinin B, and Dynorphin) in the hypothalamic arcuate nucleus generate GnRH pulses governing LH pulsatility. Kisspeptin binds KISS1R on GnRH neurons, triggering depolarization and GnRH release. The KNDy circuit has been validated as the central reproductive oscillator (Skorupskaite et al., PMID 27636018).

Kisspeptin acts via KISS1R on hypothalamic GnRH neurons, activating the HPG axis and increasing endogenous LH, FSH, and sex steroids. PT-141 (bremelanotide) acts via MC3R/MC4R in the hypothalamus, triggering sexual desire and arousal acutely and independently of hormonal changes. The mechanisms are complementary: Kisspeptin influences the basal hormonal substrate; PT-141 modulates the acute situational response.

An RCT (Owens et al., Hum Reprod 2018; N=48; PMID 29206944) demonstrated that Kisspeptin-54 as an oocyte maturation trigger in PCOS women undergoing IVF achieved fertilization rates comparable to standard hCG, with a favorable safety profile regarding ovarian hyperstimulation syndrome (OHSS) risk. Subsequent studies with analogue MVT-602 (PMID 33196464) demonstrated higher-amplitude and longer-duration LH surges.

Yes. A pilot study (Lippincott et al., JCEM 2016; N=6; PMID 27214398) demonstrated that pulsatile kisspeptin reversed IHH in individuals without spontaneous puberty, with sustained increases in LH, FSH, and testosterone after 8 weeks. A second clinical study (Chan et al., JCI Insight 2018; N=15; PMID 29669934) confirmed kisspeptin's capacity to activate the quiescent HPG axis in delayed puberty.

The KNDy (Kisspeptin/Neurokinin B/Dynorphin) circuit is the central neural oscillator of reproductive pulsatility. NKB stimulates kisspeptin secretion ("go" signal), while dynorphin inhibits it ("stop" signal), generating GnRH pulses. In vivo studies (Skorupskaite et al., PMID 27636018) demonstrated that NKB blockade potentiates kisspeptin-induced LH surges, validating this circuit architecture as the core of reproductive neuroendocrine control.

MVT-602 is a long-acting KISS1R agonist investigated as an ovulation trigger. A clinical study (Abbara et al., J Clin Invest 2020; PMID 33196464) compared MVT-602 versus native Kisspeptin-54 in women with PCOS/hypothalamic anovulation: MVT-602 induced a higher-amplitude and longer-duration LH surge, demonstrating the potential of long-acting synthetic analogues for reproductive stimulation without hCG-associated OHSS risks.

Neuroimaging (fMRI) studies in humans demonstrate that IV Kisspeptin infusion increases activity in brain regions associated with sexual attraction and motivation (amygdala, insula, anterior cingulate) in response to explicit stimuli. This effect occurs independently of acute LH/testosterone changes, suggesting direct CNS action on sexual motivation — relevant in contexts of reduced libido without apparent hormonal deficit.

In published clinical trials, Kisspeptin-54 was predominantly administered intravenously (IV) as bolus or continuous infusion, with a plasma half-life of approximately 27 minutes. Subcutaneous formulations and long-acting analogues such as MVT-602 are under investigation. Native oral kisspeptin is not bioavailable. The definitive route of administration for future clinical use is still under development.

To date, Kisspeptin has no regulatory approval as a standalone drug from any reference agency (FDA, EMA, ANVISA). Its use is restricted to clinical research protocols and assisted fertility trials at specialized centers. Long-acting KISS1R analogues such as MVT-602 are in early stages of clinical development. Any use outside formal research context is experimental.

In published clinical trials, key monitored endpoints include: LH pulses (frequency and amplitude via serial sampling), FSH, estradiol or testosterone, progesterone (post-ovulation in IVF protocols), number of mature oocytes (IVF studies), and fertilization/implantation rates. For cognition/libido studies: validated psychometric scales and fMRI responses in specific stimulation paradigms.

The theoretical combination of Kisspeptin (HPG axis activation via KISS1R → LH/testosterone → long-term hormonal substrate) with PT-141 (acute MC3R/MC4R activation → situational desire/arousal) is explored as a multimodal approach to sexual dysfunction. The two mechanisms are pharmacologically distinct and potentially complementary. ⚠️ All clinical decisions must be individualized by a qualified healthcare professional; no published clinical trials have evaluated this specific combination.